Wegovy to Zepbound: The Switch Within Obesity-Indicated Drugs

Key Takeaways

• Wegovy and Zepbound are both FDA-approved for chronic weight management. Wegovy is semaglutide 2.4 mg weekly. Zepbound is tirzepatide titrated to up to 15 mg weekly.
• Switching from Wegovy to Zepbound is common, particularly for patients seeking larger weight loss than Wegovy has produced.
• Zepbound is restarted at 2.5 mg weekly regardless of the prior Wegovy dose. Re-titration takes 5 to 6 months to reach maximum dose.
• The transition window of 4 to 8 weeks typically shows reduced appetite suppression and possible mild weight regain before Zepbound takes hold.
• Insurance coverage and supply considerations are major practical drivers of this switch alongside clinical reasons.

Direct answer

Yes, you can switch from Wegovy to Zepbound. The switch is one of the most common transitions in obesity medicine. Trial data favor Zepbound at maximum doses for larger weight loss. The switch involves restarting Zepbound at 2.5 mg weekly and titrating up over 5 to 6 months. A brief transition window is normal as the patient moves between agents. Your prescriber should make the call on timing and dose.

Table of contents

1. Wegovy and Zepbound side by side
2. Why patients switch
3. The trial data: SURMOUNT-1 vs STEP 1
4. Switching mechanics
5. The dose conversion question (and why it does not exist)
6. Timing the last Wegovy and first Zepbound dose
7. The transition window
8. Side effect comparison
9. Insurance, cost, and supply
10. When the switch makes sense and when it does not
11. FAQ
12. Sources

Wegovy and Zepbound side by side

Feature	Wegovy	Zepbound
Generic name	Semaglutide	Tirzepatide
Drug class	GLP-1 receptor agonist	Dual GLP-1/GIP agonist
FDA approval	2021 for chronic weight management	2023 for chronic weight management
Maximum dose	2.4 mg weekly	15 mg weekly
Pivotal weight loss trial	STEP 1, 14.9% mean over 68 weeks	SURMOUNT-1, 22.5% mean at 15 mg over 72 weeks
Titration schedule	Starts 0.25 mg, weekly steps to 2.4 mg over 16 weeks	Starts 2.5 mg, monthly steps to 15 mg over ~20 weeks
Manufacturer	Novo Nordisk	Eli Lilly
Pen design	Multi-dose	Single-dose autoinjector per dose strength

Why patients switch

Several patterns drive the switch from Wegovy to Zepbound.

Pattern 1: weight loss plateau. A patient on maximum Wegovy dose has reached a plateau short of their goal. The patient and prescriber consider tirzepatide for the additional effect.

Pattern 2: ceiling effect. Wegovy at 2.4 mg has produced typical weight loss (around 15% on average) but the patient wants more. Zepbound at higher doses produces larger weight loss in trials.

Pattern 3: tolerability. Some patients tolerate one drug better than the other. Cross-class differences in GI side effects are individual.

Pattern 4: insurance and supply. Coverage varies by plan and time. Supply has been periodically constrained for both drugs.

Pattern 5: cost. Eli Lilly has at various times offered savings programs and direct-to-consumer pricing for Zepbound that have shifted relative affordability.

The trial data: SURMOUNT-1 vs STEP 1

The trials are not head-to-head. The populations differed (SURMOUNT-1 was slightly heavier on average), and the trial durations differed (72 vs 68 weeks). The comparison is approximate.

SURMOUNT-1 (Jastreboff et al., NEJM 2022) randomized adults with obesity or overweight with weight-related comorbidity to tirzepatide 5, 10, or 15 mg weekly or placebo for 72 weeks. Mean body weight reductions:

• Tirzepatide 15 mg: 22.5%
• Tirzepatide 10 mg: 20.9%
• Tirzepatide 5 mg: 16.0%
• Placebo: 2.4%

STEP 1 (Wilding et al., NEJM 2021) randomized adults with obesity or overweight with comorbidity to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean body weight reduction was 14.9% with semaglutide vs 2.4% with placebo.

The implication: for patients who have reached their Wegovy plateau and want more, Zepbound's trial averages support the expectation of additional weight loss. Individual responses vary.

Switching mechanics

The mechanical switch:

1. Take your usual Wegovy injection on the scheduled day.
2. Wait approximately one week.
3. Start Zepbound 2.5 mg weekly on the day that would have been your next Wegovy injection.
4. Hold at 2.5 mg for 4 weeks.
5. Titrate to 5 mg weekly. Continue increasing by 2.5 mg every 4 weeks based on tolerability and response, up to 15 mg.

The full titration timeline to 15 mg is roughly 5 to 6 months.

The dose conversion question (and why it does not exist)

There is no validated milligram-to-milligram conversion between semaglutide and tirzepatide. Patients on Wegovy 2.4 mg do not start on a "comparable" Zepbound dose; they start at the labeled starting dose of 2.5 mg.

Some prescribers, in patients who have been on Wegovy at maximum dose for an extended period and tolerated it well, may start Zepbound at 5 mg instead of 2.5 mg. This is off-label and requires prescriber judgment about individual tolerability.

Timing the last Wegovy and first Zepbound dose

The standard transition is one week between the last Wegovy and first Zepbound dose. This matches the weekly dosing interval. Semaglutide plasma levels are still half of peak at that point, but the two drugs do not compete pharmacokinetically.

Longer gaps (2 weeks or more) mean less drug coverage during the transition. Hunger rebound and weight stabilization may be more pronounced. Patients often prefer the shorter gap.

The transition window

The first 4 to 8 weeks on Zepbound 2.5 to 5 mg are typically a transition window:

• Reduced appetite suppression compared to maximum Wegovy.
• Possible mild weight regain or stabilization.
• Reintroduction of GI side effects as the body adapts.

These stabilize as Zepbound reaches a therapeutic dose. Most patients are back on a weight-loss trajectory by week 8 to 12.

Side effect comparison

The side effect profiles are similar. Nausea, vomiting, diarrhea, constipation, and dyspepsia are the most common. Trial data suggest tirzepatide at maximum doses produces GI side effects at rates comparable to semaglutide at maximum doses.

Specific considerations:

• Both carry FDA box warnings for risk of thyroid C-cell tumors based on rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
• Acute kidney injury has been reported with both in the context of severe vomiting or diarrhea.
• Pancreatitis is a rare risk for both.
• Cholecystitis and gallstones are more common during rapid weight loss on either drug.

Insurance, cost, and supply

List prices for both drugs are in the same range. Insurance coverage is variable. Some plans cover one but not the other based on contracted pricing. Prior authorization requirements differ.

Manufacturer savings programs (Novo Nordisk for Wegovy, Eli Lilly for Zepbound) reduce out-of-pocket costs for eligible commercially insured patients. Eligibility and maximum savings change over time.

Supply has been periodically constrained for both. Patients sometimes switch because their drug is unavailable rather than for clinical preference.

When the switch makes sense and when it does not

The switch usually makes sense when:

• Wegovy has reached its plateau at maximum dose and the patient wants more weight loss.
• Insurance or supply has shifted to favor Zepbound.
• The patient has not had severe side effects on Wegovy (predicts likely tolerability on Zepbound).

The switch makes less sense when:

• The patient is doing well on Wegovy with adequate weight loss and acceptable tolerability.
• The patient has not yet reached maximum Wegovy dose (titrating further may be the better first step).
• Insurance does not cover Zepbound and cost is a barrier.
• The patient had severe side effects on Wegovy that suggest poor general GLP-1 tolerability.

The contrary view: maybe stay on Wegovy

A reasonable counterpoint: switching introduces a transition window, requires re-titration over 5 to 6 months, may bring back side effects, and may not produce additional weight loss in patients who are already excellent responders. Trial averages mask individual variation. Some patients on Wegovy have already achieved excellent outcomes. The added complexity of the switch may not be worth the marginal benefit.

That is fair. The decision should be individual, weighing actual results on Wegovy against expected gains from Zepbound.

FAQ

Can you switch from Wegovy to Zepbound?

Yes. Common transition.

Is Zepbound better than Wegovy?

Trial data favor Zepbound at maximum doses for weight loss.

Why would someone switch?

Plateau, larger expected effect, insurance, supply, tolerability.

What dose of Zepbound do I start with after Wegovy?

2.5 mg weekly, regardless of the prior Wegovy dose.

How long should I wait between drugs?

Typically one week.

Will I gain weight during the switch?

Some stabilization or mild regain in the transition window is common.

Can I switch back to Wegovy?

Yes.

Do I need a washout?

No formal washout required.

How long does it take to reach maximum Zepbound dose?

About 5 to 6 months.

Will insurance cover the switch?

Varies by plan.

Related guides

• All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia
• GLP-1 for Diabetes vs Obesity: Same Drugs, Different Doses
• What Is the Difference Between Wegovy and Zepbound: The Receptor Mechanism, Weight Loss Data, and Which One Fits Your Profile
• What Is the Difference Between Zepbound and Wegovy? Active Ingredient, Mechanism, Efficacy, and Cost Compared
• What's the Difference Between Zepbound and Wegovy: Active Ingredient, Mechanism, Efficacy, and Cost
• What's the Difference Between Wegovy and Zepbound? The Mechanism, Clinical Data, and Which Works Better

Sources

1. Novo Nordisk. Wegovy (semaglutide injection) Prescribing Information. 2021.
2. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021 (STEP 1).
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022 (SURMOUNT-1).
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
6. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
9. Coskun T et al. Pharmacology and Pharmacokinetics of Tirzepatide. Diabetes, Obesity and Metabolism. 2021.
10. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2015.
11. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
12. FDA Drug Shortages Database. GLP-1 Shortage Timelines. 2022-2024.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians. Decisions about switching between weight-management medications belong with your treating clinician.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are dispensed by 503A state-licensed pharmacies under individual prescriptions and are not interchangeable with their brand-name counterparts.

Results Disclaimer. Trial averages do not predict individual response. Weight loss outcomes after switching are variable.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with these companies.